Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents

Annals of Oncology

Volumn 18, Issue SUPPL. 5, 2007, Pages

  Fojo, Tito ^a   Menefee, M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Epothilones; Microtubulin; P glycoprotein; Paclitaxel; Taxanes; Tubulin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BMS 310705; DISCODERMOLIDE; DOCETAXEL; ELEUTHEROBIN; EPIPODOPHYLLOTOXIN DERIVATIVE; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; GLYCOPROTEIN P; ISOLAULIMALIDE; IXABEPILONE; LAULIMALIDE; MICROTUBULE STABILIZING AGENT; MULTIDRUG RESISTANCE PROTEIN 1; NATURAL PRODUCT; PACLITAXEL; SARCODICTYIN A; SARCODICTYIN B; STEROID; TACCALONOLIDE A; TACCALONOLIDE E; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; ZK 219477; TAXOID; TUBULIN MODULATOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CYTOTOXICITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG TOXICITY; MICROTUBULE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; POLYMERIZATION; PRIORITY JOURNAL; SOLID TUMOR; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM; REVIEW;

DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; MICROTUBULES; NEOPLASMS; PACLITAXEL; TAXOIDS; TUBULIN MODULATORS;

EID: 38449097524     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm172     Document Type: Conference Paper

References (53)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292.
2. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents 2002; 2: 1-17.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
4. Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin Oncol 2006; 33: 421-435.
5. Fojo AT, Ueda K, Slamon DJ et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84: 265-269.
6. Phsyician's Desk Reference, 54th edition. Montvale, NJ: Medical Economics Co 2001; 748-753: 1059-1067.
7. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998; 391: 199-203.
8. Verdier-Pinard P, Wang F, Burd B et al. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry 2003; 42: 12019-12027.
9. Luduena RF. Multiple forms of tubulin: Different gene products and covalent modifications. Int Rev Cytol 1998; 178: 207-275.
10. Galmarini CM, Kamath K, Vanier-Viornery A et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 2003; 88: 1793-1799.
11. Giodini A, Kallio MJ, Wall NR et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002; 62: 2462-2467.
12. Maney T, Wagenbach M, Wordeman L. Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J Biol Chem 2001; 276: 34753-34758.
13. Mitchison T, Kirschner M. Dynamic instability of microtubule growth. Nature 1984; 312: 237-242.
14. Dhonukshe P, Gadella TW Jr. Alteration of microtubule dynamic instability during preprophase band formation revealed by yellow fluorescent protein-CLIP170 microtubule plus-end labeling. Plant Cell 2003; 15: 597-611.
15. Vos JW, Dogterom M, Emons AM. Microtubules become more dynamic but not shorter during preprophase band formation: A possible "search-and-capture" mechanism for microtubule translocation. Cell Motil Cytoskeleton 2004; 57: 246-258.
16. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997; 13: 83-117.
17. Childs S, Ling V. The MDR superfamily of genes and its biological implications. Important Adv Oncol 1994: 21-36.
18. Goldman B. Multidrug resistance: Can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 2003; 95: 255-257.
19. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-165.
20. Szakács G, Paterson JK, Ludwig JA et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
21. Bonnet C, Boucher D, Lazereg S et al. Differential binding regulation of microtubule-associated proteins MAP1A, MAP1B, and MAP2 by tubulin polyglutamylation. J Biol Chem 2001; 276: 12839-12848.
22. Martello LA, Verdier-Pinard P, Shen HJ et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 2003; 63: 1207-1213.
23. Cabral F, Barlow SB. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 1989; 3: 1593-1599.
24. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17: 1061-1070.
25. Kavallaris M, Tait AS, Walsh BJ et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 5803-5809.
26. Jordan MA, Wendell K, Gardiner S et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816-825.
27. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999; 10: 947-959.
28. Gerth K, Bedorf N, Hofle G et al. Epothilons A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49: 560-563.
29. Mani S, Macapinlac M Jr, Goel S et al. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 2004; 15: 553-558.
30. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 1997; 272: 2534-2541.
31. Nettles JH, Li H, Cornett B et al. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science 2004; 305: 866-869.
32. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429-1437.
33. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anti-Canc Agents 2002; 2: 123-148.
34. Newman RA, Yang J, Raymond M et al. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 2001; 48: 319-326.
35. Bergstralh DT, Taxman DJ, Chou TC et al. A comparison of signaling activities induced by Taxol and desoxyepothilone B. J Chemother 2004; 16: 563-576.
36. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000; 1470: M79-M91.
37. Chou TC, Zhang XG, Balog A et al. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A 1998; 95: 9642-9647.
38. Cordon-Cardo C, O'Brien JP, Boccia J et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-1287.
39. Bode CJ, Gupta ML Jr, Reiff EA et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41: 3870-3874.
40. Gunasekera SP, Paul GK, Longley RE et al. Five new discodermolide analogues from the marine sponge Discodermia species. J Nat Prod 2002; 65: 1643-1648.
41. Longley RE, Caddigan D, Harmody D et al. Discodermolide - a new, marine-derived immunosuppressive compound. I. In vitro studies. Transplantation 1991; 52: 650-656.
42. ter Haar E, Kowalski RJ, Hamel E et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol. Biochemistry 1996; 35: 243-250.
43. Kowalski RJ, Giannakakou P, Gunasekera SP et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52: 613-622.
44. Martello LA, McDaid HM, Regl DL et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000; 6: 1978-1987.
45. Klein LE, Freeze BS, Smith AB III, Horwitz SB. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle 2005; 4: 501-507.
46. Martello LA, LaMarche MJ, He L et al. The relationship between Taxol and (+)- discodermolide: Synthetic analogs and modeling studies. Chem Biol 2001; 8: 843-855.
47. Honore S, Kamath K, Braguer D et al. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 2004; 64: 4957-4964.
48. Mita A, Lockhart A, Chen T. A phase I pharmacokinetic (PK) of AAA296A (Discodermolide) administered every 3 weeks in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 2004; 23: 133 (Abstr 2025).
49. Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: Effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999; 38: 5490-5498.
50. Mooberry SL, Tien G, Hernandez AH et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999; 59: 653-660.
51. Tinley TL, Randall-Hlubek DA, Leal RM et al. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 2003; 63: 3211-3220.
52. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr Pharm Des 1999; 5: 139-162.
53. Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat 2001; 4: 392-401.